Moreover, Vacc DCs also upregulated number of DCs that were MHCI + CD86 + CD11c+ in the tumour as compared to other treatment groups, suggesting the Vacc DCs support the activation of DCs in vivo (Fig. 5f). This evidence concerns the gene CD86 and neoplasm.